One in Three Americans Will Have Diabetes by 20501

>400 million

Number of people with type 2 diabetes worldwide2,3

>240 million

Estimated number of obese type 2 diabetes patients who are refractory to oral medication3,4,5

>60%

Percentage of type 2 diabetes patients who are obese5

>$800 billion

Yearly cost of diabetes treatment globally2

$27 billion

Yearly global expenditure on insulin6

Up to 94%

Percentage of insulin users who show symptoms of anxiety and distress from insulin injections7

Decreasing HbA1c by 1% lowers risks8

lowered risk of death related to diabetes

decrease in risk of microvascular complications

lowered myocardial infraction risk

Current Challenges in the Management of Diabetes

“Many patients don’t want to use insulin. They don’t want to do finger sticks and they’re afraid of hypoglycemia.” Prof. Harold Lebovitz, State University of New York Health Science Center, Brooklyn, New York

… While there have been remarkable advancements in recent years, there continue to be deficits in type 2 diabetes therapies. An optimal treatment would meaningfully reduce HbA1c, minimize patient adherence as a factor in treatment efficacy, and have minimal side effects. If this were achieved, the consumption of healthcare resources could be significantly reduced while improving the lives of millions of patients.

… While there have been remarkable advancements in recent years, there continue to be deficits in type 2 diabetes therapies…

Read More

Sources

[1] Boyle JP, Thompson TJ, Gregg EW, Barker LE, Williamson DF. Projection of the year 2050 burden of diabetes in the US adult population: dynamic modeling of incidence, mortality, and prediabetes prevalence. Popul Health Metr. 2010;8:29. [2] Global Report on Diabetes. World Health Organization, 2016 [3] United States Census Bureau 2015, Accessed 18 August 2015. [4] MetaCure estimates, 2015. [5] Wong SK, Kong AP, Luk AO, et al. A pilot study to compare meal-triggered gastric electrical stimulation and insulin treatment in Chinese obese type 2 diabetes. Diabetes Technol Ther. 2015;17(4):283-90. [6] Human Insulin Market Development and Demand Forecast to 2020, P&S Market Research, 2015. [7] Aronson R. The role of comfort and discomfort in insulin therapy. Diabetes Technol Ther. 2012;14(8):741-7. ix. [8] Stratton IM, Adler AI, Neil HA, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ. 2000;321(7258):405-12.